PLASMINOGEN-ACTIVATOR INHIBITOR AND VONWILLEBRAND-FACTOR IN POLYMYALGIA RHEUMATICA

被引：12

作者：

UDDHAMMAR, A

RANTAPAADAHLQVIST, S

NILSSON, TK

机构：

[1] Department of Rheumatology, University Hospital, Umeå

[2] Department of Clinical Chemistry, University Hospital, Umeå

来源：

CLINICAL RHEUMATOLOGY | 1992年 / 11卷 / 02期

关键词：

POLYMYALGIA RHEUMATICA; PLASMINOGEN ACTIVATOR INHIBITOR; VONWILLEBRAND FACTOR; ACUTE PHASE PROTEINS;

D O I：

10.1007/BF02207959

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Endothelial cell products, plasminogen activator inhibitor (PAI) and von Willebrand factor (vWF), were assayed in 25 patients with newly-diagnosed and untreated polymyalgia rheumatica (PMR), before and after three and 12 months of corticosteroid treatment. The mean values of PAI and vWF, and also the levels of acute phase reactants (erythrocyte sedimentation rate, fibrinogen, haptoglobin, orosomucoid, C-reactive protein) and platelet counts, were elevated in the active untreated disease. In contrast to the acute phase proteins, both PAI and vWF remained increased after three and 12 months of glucocorticoid treatment. This suggested an active vasculitis, despite a clinically-inactive disease. Particularly high levels of vWF both before and after glucocorticoid therapy were found in two patients who subsequently developed vascular complications during the follow-up period.

引用

页码：211 / 215

页数：5

共 26 条

[1]

Bengtsson B.A., Malmwall B.E., The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica, Arthritis Rheum, 24, pp. 899-904, (1981)

[2]

Persellin S.T., Daniels T.M., Rings L.J., Kazmier F.J., Bowie E.J.W., Hunder C.G., Factor VIII-von Willebrand factor in giant cell arteritis and polymyalgia rheumatica, Mayo Clin Proc, 60, pp. 457-462, (1985)

[3]

Sprengers E.D., Kluft C., Plasminogen activator inhibitors, Blood, 69, pp. 381-382, (1987)

[4]

Jaffe E.A., Hoyer L.W., Nachman R.L., Synthesis of von Willebrand factor by cultured human endothelial cells, Proc Natl Acad Sci (USA), 71, pp. 1906-1909, (1974)

[5]

Mellbring G., Nilsson T., Bergsdorf N., Wallen P., Tissue plasminogen activator concentrations in major abdominal surgery. Relationship to postoperative deep vein thrombosis, Thromb Res, 36, pp. 331-334, (1984)

[6]

Kluft C., Verheyijen J.H., Jie A.F.H., Rijken D.C., Preston F.E., Sue-Ling H.M., Jespersen J., Aasen A.O., The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma, Scand J Clin Lab Invest, 45, pp. 605-610, (1985)

[7]

Korninger C., Lechner K., Niessner H., Gossinger H., Kundi M., Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis, Thromb Haemostas, 52, pp. 129-130, (1984)

[8]

Haten A., Waldius G., Szamosi A., Blomback M., de Faire U., Dahlen G., Landou C., Wiman B., Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction, Lancet, 2, pp. 3-9, (1987)

[9]

Awada H., Barlowatz-Meimon G., Dougados M., Maisonneuve P., Sultan Y., Amor B., Fibrinolysis abnormalities in systemic lupus erythematosus and their relation to vasculitis, J Lab Clin Med, 111, pp. 229-236, (1988)

[10]

Woolf A.D., Wakerley G., Wallington T.B., Scott D.G.I., Dieppe P.A., Factor VIII related antigen in the assessment of vasculitis, Ann Rheum Dis, 46, pp. 441-447, (1987)

← 1 2 3 →